MINDSET 2 – Neuroprogressive and Dementia Network

0AdIsfFCnB8Ofaj Cbp3Te35iHYCASK 2Q7JVN9 rmI

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease

A new clinical trial, titled Mindset 2: A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease , is set to commence shortly. This large-scale phase 3 trial is investigating whether two medications – KarXT + KarX-EC – can improve memory and thinking problems in people with Alzheimer’s Disease. More information can be found here.

This study is in setup

To find out more about this research study, please contact:
loth.sdcrn@nhs.scot
0131 537 3804

Key Staff

Bio Pic removebg preview — NDN Study Lead: Bev Goldberg

This is looking at patients with mild to moderate Alzheimer’s Disease.

CONTACT INFORMATION

Neuroprogressive & Dementia Research Network Office

Old Pharmacy Building
Western General Hospital
Edinburgh
EH4 2XU

Email: loth.sdcrn@nhs.scot

Telephone: 0131 537 3804

ABOUT US

The NRS Neuroprogressive Disease and Dementia Network team in NHS Lothian conduct commercial and investigator led studies for: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Motor Neurone Disease, dementia with Lewy bodies, Progressive Supranuclear Palsy and Multiple System Atrophy.